Jun 15, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
BioCryst Reports New Data From Its Phase 2 Forodesine Study In Patients With Chronic
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2425420" data-attributes="member: 124445"><p>BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the presentation of new data that confirms forodesine's clinical activity in the treatment of chronic lymphocytic leukemia (CLL) at the 52nd Annual American Society of Hematology (ASH) Meeting & Exposition being held in Orlando, Florida. In this Phase 2, open-label, single-arm, multi-center study, forodesine was administered orally at 200 mg twice-daily for 28-day cycles in previously treated CLL patients. The primary endpoint of the study was overall response rate...<a href="http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/r_pqpE8AyZo" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/r_pqpE8AyZo/3NPy" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2425420, member: 124445"] BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the presentation of new data that confirms forodesine's clinical activity in the treatment of chronic lymphocytic leukemia (CLL) at the 52nd Annual American Society of Hematology (ASH) Meeting & Exposition being held in Orlando, Florida. In this Phase 2, open-label, single-arm, multi-center study, forodesine was administered orally at 200 mg twice-daily for 28-day cycles in previously treated CLL patients. The primary endpoint of the study was overall response rate...[URL="http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/0/da"][IMG]http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/1/da"][IMG]http://feedads.g.doubleclick.net/~a/YfPVLqn4_oqvXCFCTlulrQ_g-hE/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/r_pqpE8AyZo[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/r_pqpE8AyZo/3NPy]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top